{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:49:59Z","timestamp":1793893799538,"version":"4.8.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a potentially life-threatening, systemic autoimmune disease with a high risk for relapse and treatment-related toxicity, making AAV a high-costs illness. This study aimed to identify clinical insights for clinicians on considering this costs burden.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a detailed, retrospective, single-centre, activity-based cost-analysis and identified clinical variables associated with increased costs. We analysed real-world costs incurred by the hospital between January 2018 and December 2019, omitting the outpatient pharmacy expenditures. Our cohort included both incident and prevalent AAV patients with at least 6 months of follow-up since diagnosis, indicating survival beyond initial diagnosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>For 180 AAV patients with a median follow-up of 1.8 years the average hospital costs incurred amounted to \u20ac9887 per patient year, with inpatient care being the primary cost driver (32%). Merely 15% of costs were attributable to patients experiencing relapse (N\u00a0=\u00a014\/180, 8%). More importantly, 71% of costs were attributable to patients experiencing infections (N\u00a0=\u00a077\/180, 43%). Likewise, 60% of costs were attributable to patients with multi-comorbidity (N\u00a0=\u00a065\/180, 36%). Infections and multi-comorbidity were both strongly associated with corticosteroid (CS) use. Regression and sensitivity analyses suggest that a reduction of infections, comorbidities and maintenance treatment with CS will reduce hospital costs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This real-world cost analysis demonstrates that the burden of infections and comorbidities, both related to CS use, is higher than that of relapses on hospital costs in AAV patients. Thus, this study implicates clinicians considering hospital costs should focus on reducing CS and achieving CS-free remission to prevent infections and comorbidities.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfaf267","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T15:32:18Z","timestamp":1756481538000},"source":"Crossref","is-referenced-by-count":2,"title":["Drivers of hospital costs in ANCA-associated vasculitis patients with long-term follow-up\u2014a real-world cost analysis"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-7566","authenticated-orcid":false,"given":"Jolijn R","family":"van Leeuwen","sequence":"first","affiliation":[{"name":"Center of Expertise for Lupus-, Vasculitis- and Complement-mediated Systemic diseases (LuVaCs) , Department of Internal Medicine \u2013 Nephrology section, Leiden University Medical Center, Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frouzan H","family":"Soltani","sequence":"additional","affiliation":[{"name":"Center of Expertise for Lupus-, Vasculitis- and Complement-mediated Systemic diseases (LuVaCs) , Department of Internal Medicine \u2013 Nephrology section, Leiden University Medical Center, Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert B","family":"van den Hout","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center Department of Medical Decision Making, , Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6780-5186","authenticated-orcid":false,"given":"Ton J","family":"Rabelink","sequence":"additional","affiliation":[{"name":"Center of Expertise for Lupus-, Vasculitis- and Complement-mediated Systemic diseases (LuVaCs) , Department of Internal Medicine \u2013 Nephrology section, Leiden University Medical Center, Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9920-2195","authenticated-orcid":false,"given":"Y K Onno","family":"Teng","sequence":"additional","affiliation":[{"name":"Center of Expertise for Lupus-, Vasculitis- and Complement-mediated Systemic diseases (LuVaCs) , Department of Internal Medicine \u2013 Nephrology section, Leiden University Medical Center, Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"2025091920005214800_bib1","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","journal-title":"Ann Rheum Dis"},{"key":"2025091920005214800_bib2","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"2025091920005214800_bib3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025091920005214800_bib4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/art.41557","article-title":"Multimorbidity in antineutrophil cytoplasmic antibody-associated vasculitis: results from a longitudinal, multicenter data linkage study","volume":"73","author":"Sarica","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025091920005214800_bib5","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1016\/S2665-9913(23)00030-9","article-title":"Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial","volume":"5","author":"Patel","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2025091920005214800_bib6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"2025091920005214800_bib7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/rheumatology\/kez001","article-title":"A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"58","author":"Pepper","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025091920005214800_bib8","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2025091920005214800_bib9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/ard-2023-224343","article-title":"Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study","volume":"83","author":"Furuta","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025091920005214800_bib10","first-page":"1249","article-title":"Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States","volume":"27","author":"Bell","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"2025091920005214800_bib11","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.3899\/jrheum.150479","article-title":"Clinical and economic burden of antineutrophil cytoplasmic antibody-associated vasculitis in the United States","volume":"42","author":"Raimundo","year":"2015","journal-title":"J Rheumatol"},{"key":"2025091920005214800_bib12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.semarthrit.2017.08.005","article-title":"Healthcare utilization and expenditures for United States Medicare beneficiaries with systemic vasculitis","volume":"47","author":"Thorpe","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2025091920005214800_bib13","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1007\/s12325-023-02681-0","article-title":"Profile, healthcare resource consumption and related costs in ANCA-associated vasculitis patients: a real-world analysis in Italy","volume":"40","author":"Degli Esposti","year":"2023","journal-title":"Adv Ther"},{"key":"2025091920005214800_bib14","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s11739-020-02431-y","article-title":"Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases","volume":"16","author":"Quartuccio","year":"2021","journal-title":"Intern Emerg Med"},{"key":"2025091920005214800_bib15","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s40744-024-00714-w","article-title":"Disease Overlap, healthcare resource utilization, and costs in patients with eosinophilic granulomatosis with polyangiitis: a REVEAL sub-study","volume":"11","author":"Xu","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2025091920005214800_bib16","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3899\/jrheum.101149","article-title":"The accuracy of administrative data diagnoses of systemic autoimmune rheumatic diseases","volume":"38","author":"Bernatsky","year":"2011","journal-title":"J Rheumatol"},{"key":"2025091920005214800_bib17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejim.2022.05.017","article-title":"Validation of anti-neutrophil cytoplasm antibodies associated vasculitides diagnosis codes from the electronic health records of two French university hospitals","volume":"103","author":"Mettler","year":"2022","journal-title":"Eur J Intern Med"},{"key":"2025091920005214800_bib18","doi-asserted-by":"publisher","first-page":"107757","DOI":"10.1016\/j.compbiomed.2023.107757","article-title":"Using an artificial intelligence tool incorporating natural language processing to identify patients with a diagnosis of ANCA-associated vasculitis in electronic health records","volume":"168","author":"van Leeuwen","year":"2024","journal-title":"Comput Biol Med"},{"key":"2025091920005214800_bib19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1055\/s-0038-1672208","article-title":"Activity-based costing","volume":"32","author":"Jalalabadi","year":"2018","journal-title":"Semin Plast Surg"},{"key":"2025091920005214800_bib20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/hec.1363","article-title":"The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs gross-costing approaches","volume":"18","author":"Clement Nee Shrive","year":"2009","journal-title":"Health Econ"},{"key":"2025091920005214800_bib21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40273-015-0325-4","article-title":"Cost-of-illness studies: an updated review of current methods","volume":"34","author":"Onukwugha","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"2025091920005214800_bib22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s10198-004-0259-9","article-title":"Collecting unit cost data in multicentre studies. Creating comparable methods","volume":"6","author":"Wordsworth","year":"2005","journal-title":"Eur J Health Econ"},{"key":"2025091920005214800_bib23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jclinepi.2020.11.014","article-title":"Text-mining in electronic healthcare records can be used as efficient tool for screening and data collection in cardiovascular trials: a multicenter validation study","volume":"132","author":"van Dijk","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"2025091920005214800_bib24","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.3390\/cancers14215426","article-title":"Application of electronic health record text mining: real-world tolerability, safety, and efficacy of adjuvant melanoma treatments","volume":"14","author":"van Laar","year":"2022","journal-title":"Cancers"},{"key":"2025091920005214800_bib25"},{"key":"2025091920005214800_bib26","doi-asserted-by":"publisher","first-page":"902423","DOI":"10.3389\/fmed.2022.902423","article-title":"Secular Trends of incidence, prevalence, and healthcare economic burden in ANCA-associated vasculitis: an analysis of the 2002-2018 South Korea National Health Insurance Database","volume":"9","author":"Ahn","year":"2022","journal-title":"Front Med"},{"key":"2025091920005214800_bib27","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2025091920005214800_bib28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/rheumatology\/keu366","article-title":"Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials","volume":"54","author":"Robson","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2025091920005214800_bib29","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.34067\/KID.0000502021","article-title":"Glucocorticoid therapy in ANCA vasculitis: using the Glucocorticoid Toxicity Index as an outcome measure","volume":"2","author":"Floyd","year":"2021","journal-title":"Kidney360"},{"key":"2025091920005214800_bib30","unstructured":"Merkel P, Pagnoux M, Khalidi N \u00a0et al. \u00a0A multicenter, randomized, controlled trial evaluating the effects of low-dose glucocorticoids compared to stopping glucocorticoids to maintain remission of granulomatosis with polyangiitis: the TAPIR trial. In: 21st International Vasculitis Workhop Abtracts book, Zenodo; 2024. [Internet] https:\/\/doi.org\/10.5281\/zenodo.11068008. Available from: https:\/\/vasculitis-barcelona2024.com\/index.php\/abstracts\/abstracts-book (10 November 2024, date last accessed)."},{"key":"2025091920005214800_bib31","first-page":"782","article-title":"Key considerations for modelling the long-term costs and benefits of treatments for ANCA-associated vasculitis","volume":"42","author":"Berdunov","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"2025091920005214800_bib32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/14737167.2023.2297790","article-title":"A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain","volume":"24","author":"Macia","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf267\/64162436\/sfaf267.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/9\/sfaf267\/64162436\/sfaf267.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/9\/sfaf267\/64162436\/sfaf267.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:01:02Z","timestamp":1758326462000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf267\/8244161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf267","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,29]]},"article-number":"sfaf267"}}